FIG Invests in Elitepharm to Integrate AI in Nutraceuticals

February 17, 2025
Freedom International Group (FIG) has announced a strategic investment in Elitepharm Laboratoires, aiming to enhance dietary supplement production with AI technology.

Freedom International Group (FIG) has announced a strategic investment in Elitepharm Laboratoires, as stated in a press release. This move positions FIG as a major shareholder in Elitepharm, a leading French company specializing in the formulation and production of dietary supplements.

The investment aims to leverage AI technology to improve the efficiency and effectiveness of dietary supplement production. Narek Sirakanyan, President and CEO of FIG, highlighted the strategic importance of this investment, noting that France's regulatory environment and technological advancements make it an ideal location for producing dietary supplements.

Elitepharm plans to use this investment to accelerate its commercial and industrial development. The company intends to strengthen its existing facilities, acquire new production sites, and expand its private label portfolio. This expansion is part of a broader strategy to enhance control over the value chain and ensure high-quality production standards.

The partnership between FIG and Elitepharm is based on a shared vision of innovation and industrial excellence, with the goal of establishing Elitepharm as a major player in the European market by 2029.

We hope you enjoyed this article.

Consider subscribing to one of our newsletters like AI Funding Brief, Life AI Weekly or Daily AI Brief.

Also, consider following us on social media:

AI Funding News Healthcare & Life Sciences AI AI Brief AI Brief (X)

More from: Funding

07/30
Promptfoo Secures $18.4M to Enhance AI Security
07/30
JotPsych Secures $5M to Develop AI-Driven EHR
07/30
Magentiq Eye Secures Series A Funding for AI Gastroenterology Software
07/30
CSP Associates Acquires Majority Stake in Tamarack Defense
07/30
Plutus Launches AI Solutions for Insurance with Moneta Ventures Backing

More from: Life Sciences

07/30
Moberg Analytics and NXT Humans Launch AI Platform for Brain Injury Care
07/30
JotPsych Secures $5M to Develop AI-Driven EHR
07/30
Magentiq Eye Secures Series A Funding for AI Gastroenterology Software
07/30
Surgical Safety Technologies Integrates Kinematic Data into OR Black Box
07/30
PRC Enhances VoicesAI with Meta's LLaMA for Healthcare Insights

Subscribe to Life AI Weekly

Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.

AI Token Webinar

Whitepaper

Stanford HAI’s 2025 AI Index Reveals Record Growth in AI Capabilities, Investment, and Regulation

The 2025 AI Index by Stanford HAI provides a comprehensive overview of the global state of artificial intelligence, highlighting significant advancements in AI capabilities, investment, and regulation. The report details improvements in AI performance, increased adoption in various sectors, and the growing global optimism towards AI, despite ongoing challenges in reasoning and trust. It serves as a critical resource for policymakers, researchers, and industry leaders to understand AI's rapid evolution and its implications.

Read more

You May Also Like